Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291576 | 0.85 | TLR7 (0.38) | CNR2CNR1TAS2R14RORC | |
| SCHEMBL18291401 | 0.84 | FFAR2 (0.35) | CNR2CNR1TAS2R14RORCCSF1R | |
| SCHEMBL20255410 | 0.84 | FFAR2 (0.35) | CNR2CNR1TAS2R14RORCCSF1R | |
| SCHEMBL20249123 | 0.82 | ALDH1A1 (0.45) | — | |
| SCHEMBL20249120 | 0.82 | ALDH1A1 (0.45) | — | |
| SCHEMBL20249122 | 0.80 | CNR2 (0.41) | CNR2CNR1RORCGCK | |
| SCHEMBL20249152 | 0.77 | SLC6A2 (0.36) | CNR2CNR1 | |
| SCHEMBL20249183 | 0.72 | ALDH1A1 (0.40) | TAS2R14 | |
| SCHEMBL10328556 | 0.70 | TAS2R14 (0.60) | CNR2CNR1TAS2R14 | |
| SCHEMBL18291553 | 0.67 | SMN1; SMN2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CNR2 2055/4885CNR1 1966/4885TAS2R14 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.